A fejlesztés 3. évében 8 új molekuláris diagnosztikai szolgáltatást fejlesztett ki a Konzorcium az emlőrák, vastagbélrák, tüdőrák, GIST és melanoma prognosztikája és predikciója számára. A kutatási periódusban 2 szabadalmat jelentett be új típusú mitogén/motogén jelpálya-módosításra. Emberi daganatok preklinikai modelljein az eritropoetin erekre gyakorolt hatásainak funkcionális képalkotó vizsgálatokkal történő mérését dolgozta ki. Humán melanoma modelleken a szisztémás progresszió genomikai jellemzőit határozta meg.
1 Antoniou, AC, Cunningham, AP, Oláh, E et al. 2008 The BOADICEA model of genetic susceptibility to breast and ovarian cancer: updates and extensions Br J Cancer 98 1457–1466.
2 Linger, R, Dudakia, D, Oláh, E et al. 2008 Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors Genes Chromosomes Cancer 47 247–252.
3 Nagahashi, M, Ajioka, Y, Lang, I, Szentirmay, Z et al. 2008 Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary World J Gastroenterol 14 70–75.
4 Illés, A, Simon, Z, Tóth, E et al. 2008 Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) – Clinicopathological features based on the data of two Hungarian lymphoma centres Pathol Oncol Res 14 411–421.
5 Szőke, J, Csernák, E, Szentirmay, Z 2008 Mutational analysis of the epidermal growth factor receptor gene in clinical samples of adenocarcinoma of the lung Revis Med Farmac 54 Suppl 3 495–498.
6 Kovács, ME, Papp, J, Szentirmay, Z et al. 2009 Deletions removing the last exon of TACSTD’ constitute a distinct class of mutations predisposing to Lynch syndrome Hum Mutat 30 197–203.
7 Dome, B, Dobos, J, Tovari, J et al. 2008 Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization and therapeutic considerations in malignant disease Cytometry A 73 186–193.
8 Lövey, J, Bereczky, B, Gilly, R et al. 2008 Recombinant human erythropoietin-alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels Strahlenther Oncol 184 1–7.
9 Amir, E, Hughes, S, Blackhall, F et al. 2008 Targeting blood vessels for the treatment of non-small cell lung cancer Curr Cancer Drug Targets 8 392–403.
10 Dome, B, Timar, J, Ladanyi, A et al. 2009 Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy Crit Rev Oncol Hematol 69 108–124.
11 Bogos, K, Renyi-Vamos, F, Dobos, J et al. 2009 High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer Clin Cancer Res 15 1741–1746.
12 Tímár, J, Döme, B 2008 Antiangiogenic drugs and tyrosine kinases Anticancer Agents Med Chem 5 462–469.
13 Tóvári, J, Pirker, R, Tímár, J et al. 2008 Erythropoietin in cancer: an update Curr Mol Med 8 481–491.
14 Dome, P, Teleki, Z, Rihmer, Z et al. 2009 Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul Mol Psychiatry 14 523–531.
15 Tímár, J, Győrffy, B, Rásó, E. Gene signature of the metastatic potential of cutaneous melanoma. Clin Exp Metast 2009 (in press).
16 Réti, A, Barna, G, Pap, E et al. 2008 Enhancement of 5-fluorouracyl efficacy on high COX-2 expressing HCA-7 cells by low dose indomethacin and NS-398 but not on low COX-2 expressing HT-29 cells Pathol Oncol Res 1007/s12253-008-9126-9.
17 Kralovánszky, J 2008 Törekvések a daganatkemoterápia hatékonyságának fokozására Magyar Onkológia 52 9–18.
18 Komlósi, V, Budai, B, Adleff, V, et al. Serine hydroxymethyltransferase (SHMT) C1420T and methylenetetrahydrofolate reductase C677T polymorphisms in colorectal cancer and their influence on the serum homocysteine level. Eur J Hum Genet, Manuscript number: 740-08-EWJHG (Submitted 2008).
19 Bácsi, K, Hitre, E, Kósa, JP et al. 2008 Effects of the lactase 13910C/T and calcium-sensor receptor A986S G/T gene polymorphisms on the incidence and recurrence of colorectal cancer in Hungarian population BMC Cancer 8 317.